

William T Abraham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9949656/publications.pdf>

Version: 2024-02-01

191
papers

15,051
citations

36691

53
h-index

22488

117
g-index

191
all docs

191
docs citations

191
times ranked

11600
citing authors

#	ARTICLE	IF	CITATIONS
1	Age-Related Outcomes After Transcatheter Mitral Valve Repair in Patients With Heart Failure. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 397-407.	1.1	8
2	The V-LAP System for Remote Left Atrial Pressure Monitoring of Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 963-972.	0.7	20
3	Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation. <i>Heart</i> , 2022, , heartjnl-2021-320005.	1.2	14
4	Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 41-49.	1.9	15
5	Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial. <i>European Heart Journal</i> , 2022, 43, 1639-1648.	1.0	14
6	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 504-510.	1.2	21
7	Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12.	1.9	26
8	A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 175-185.	2.9	30
9	Wireless Hemodynamic Monitoring in Patients with Heart Failure. <i>Current Heart Failure Reports</i> , 2021, 18, 12-22.	1.3	3
10	3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1029-1040.	1.2	113
11	Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. <i>Circulation: Heart Failure</i> , 2021, 14, e007564.	1.6	17
12	Remote Hemodynamic-Guided Therapy of Patients With Recurrent Heart Failure Following Cardiac Resynchronization Therapy. <i>Journal of the American Heart Association</i> , 2021, 10, e017619.	1.6	20
13	Interatrial shunting for the treatment of heart failure: an on-demand, self-regulating left atrial pressure lowering system. <i>European Journal of Heart Failure</i> , 2021, 23, 811-813.	2.9	4
14	Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes. <i>JAMA Cardiology</i> , 2021, 6, 427.	3.0	49
15	Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010300.	1.4	39
16	Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 879-889.	1.1	32
17	Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 515-526.	1.4	30
18	Feasibility of remote speech analysis in evaluation of dynamic fluid overload in heart failure patients undergoing haemodialysis treatment. <i>ESC Heart Failure</i> , 2021, 8, 2467-2472.	1.4	7

#	ARTICLE	IF	CITATIONS
19	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021, 110, 1334-1349.	1.5	4
20	Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008212.	1.6	8
21	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53.	1.2	3
22	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. <i>Circulation</i> , 2021, 144, 1265-1267.	1.6	5
23	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the <i>ADRB1</i> Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009591.	2.1	5
24	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 559-567.	1.9	6
25	Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial. <i>ESC Heart Failure</i> , 2021, 8, 3472-3482.	1.4	26
26	Device Therapy in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 931-956.	1.2	50
27	Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure. <i>Circulation</i> , 2021, 144, 426-437.	1.6	68
28	Left Ventricular Global Longitudinal Strain as a Predictor of Outcomes in Patients with Heart Failure with Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 955-965.	1.2	14
29	Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation. <i>JACC: Heart Failure</i> , 2021, 9, 684-692.	1.9	8
30	Pulmonary Artery Pressure Monitoring Effectively Guides Management to Reduce Heart Failure Hospitalizations in Obesity. <i>JACC: Heart Failure</i> , 2021, 9, 784-794.	1.9	4
31	Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 674-683.	1.9	19
32	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117
33	Right Ventricular-Pulmonary Arterial Coupling in Patients With HF Secondary MR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2231-2242.	1.1	38
34	Direct Interstitial Decongestion in an Animal Model of Acute-on-Chronic Ischemic Heart Failure. <i>JACC Basic To Translational Science</i> , 2021, 6, 872-881.	1.9	13
35	Dose Limiting, Adverse Event Associated Bradycardia with β -blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial. <i>Heart Rhythm O2</i> , 2021, 3, 40-49.	0.6	0
36	Apneas of Heart Failure and Phenotype-Guided Treatments. <i>Chest</i> , 2020, 157, 394-402.	0.4	24

#	ARTICLE	IF	CITATIONS
37	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. American Heart Journal, 2020, 219, 1-8.	1.2	27
38	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 528-538.	2.9	28
39	Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation. Journal of the American College of Cardiology, 2020, 76, 1007-1014.	1.2	34
40	Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2331-2341.	1.1	16
41	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. European Journal of Heart Failure, 2020, 22, 2175-2186.	2.9	23
42	Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation. Journal of the American College of Cardiology, 2020, 76, 2595-2606.	1.2	27
43	Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378.	1.2	35
44	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC: Heart Failure, 2020, 8, 961-972.	1.9	15
45	Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy. Circulation: Heart Failure, 2020, 13, e007293.	1.6	20
46	Impact of COPD on Outcomes After MitraClip for Secondary Mitral Regurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2795-2803.	1.1	14
47	Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure. Circulation: Heart Failure, 2020, 13, e006863.	1.6	125
48	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.	2.9	14
49	Impact of Tricuspid Regurgitation on Clinical Outcomes. Journal of the American College of Cardiology, 2020, 76, 1305-1314.	1.2	63
50	Cardiac safety research consortium shock think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. American Heart Journal, 2020, 230, 93-97.	1.2	14
51	Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure. Circulation: Heart Failure, 2020, 13, e006731.	1.6	37
52	Optimizer Smart in the treatment of moderate-to-severe chronic heart failure. Future Cardiology, 2020, 16, 13-25.	0.5	16
53	Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. European Journal of Heart Failure, 2020, 22, 1803-1813.	2.9	75
54	The Use of MitraClip in Secondary Mitral Regurgitation and Heart Failure. Cardiovascular Revascularization Medicine, 2020, 21, 1606-1612.	0.3	3

#	ARTICLE	IF	CITATIONS
55	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
56	Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2099-2106.	1.2	24
57	In-Hospital Management of Sleep Apnea During Heart Failure Hospitalization: A Randomized Controlled Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 705-712.	0.7	15
58	Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1-13.	1.2	121
59	Future research prioritization in cardiac resynchronization therapy. <i>American Heart Journal</i> , 2020, 223, 48-58.	1.2	13
60	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 432.	3.0	59
61	The clinical characteristics of lower extremity lymphedema in 440 patients. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 851-859.	0.9	43
62	The prevalence and importance of frailty in heart failure with reduced ejection fraction: An analysis of PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020, 22, 2123-2133.	2.9	85
63	Endpoints in Heart Failure Drug Development. <i>JACC: Heart Failure</i> , 2020, 8, 429-440.	1.9	28
64	Who and when to clip: that is the question. <i>European Journal of Heart Failure</i> , 2020, 22, 20-22.	2.9	1
65	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , 2019, 7, 913-921.	1.9	6
66	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population. <i>JACC: Heart Failure</i> , 2019, 7, 586-598.	1.9	22
67	Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. <i>Sleep</i> , 2019, 42, .	0.6	40
68	Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2969-2979.	1.2	161
69	Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT) trial. <i>American Heart Journal</i> , 2019, 217, 13-22.	1.2	23
70	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). <i>American Heart Journal</i> , 2019, 214, 18-27.	1.2	41
71	Imaging Device Therapy. <i>Heart Failure Clinics</i> , 2019, 15, 305-320.	1.0	0
72	Income Inequality and Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 336-346.	1.9	63

#	ARTICLE	IF	CITATIONS
73	A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience. <i>Journal of Cardiovascular Translational Research</i> , 2019, 12, 290-298.	1.1	29
74	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019, 73, 29-40.	1.2	168
75	Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMO-VAD pilot study. <i>ESC Heart Failure</i> , 2019, 6, 194-201.	1.4	29
76	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019, 21, 577-587.	2.9	38
77	Phrenic nerve stimulation in patients with central sleep apnea: a single-center experience from pilot and pivotal trials evaluating the remed ^Å System. <i>Kardiologia Polska</i> , 2019, 77, 553-560.	0.3	2
78	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1747-1755.	1.4	20
79	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 888-895.	2.9	93
80	Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. <i>American Journal of Cardiology</i> , 2018, 121, 1400-1408.	0.7	30
81	The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design. <i>American Heart Journal</i> , 2018, 201, 141-148.	1.2	22
82	Improving Heart Failure Therapeutics Development in the United States. <i>Journal of the American College of Cardiology</i> , 2018, 71, 443-453.	1.2	40
83	The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 780-791.	2.9	81
84	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018, 199, 51-58.	1.2	9
85	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , 2018, 266, 187-192.	0.8	27
86	Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education. <i>American Journal of Medicine</i> , 2018, 131, 974-978.	0.6	13
87	Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1325-1333.	1.2	14
88	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <sc>ATMOSPHERE</sc> trial. <i>European Journal of Heart Failure</i> , 2018, 20, 136-147.	2.9	18
89	The Utility of a Wireless Implantable Hemodynamic Monitoring System in Patients Requiring Mechanical Circulatory Support. <i>ASAIO Journal</i> , 2018, 64, 301-308.	0.9	31
90	Transcatheter Mitral-Valve Repair in Patients with Heart Failure. <i>New England Journal of Medicine</i> , 2018, 379, 2307-2318.	13.9	2,079

#	ARTICLE	IF	CITATIONS
91	Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1746-1754.	2.9	64
92	Dose Response of β -Blockers in Adrenergic Receptor Polymorphism Genotypes. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002210.	1.6	8
93	Interatrial Shunting for Heart Failure. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2300-2310.	1.1	80
94	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. <i>American Heart Journal</i> , 2018, 205, 1-11.	1.2	84
95	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. <i>JACC: Heart Failure</i> , 2018, 6, 874-883.	1.9	159
96	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. <i>American Heart Journal</i> , 2018, 204, 139-150.	1.2	27
97	Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	20
98	Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. <i>European Heart Journal</i> , 2017, 38, ehw506.	1.0	22
99	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	79
100	Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor. <i>Circulation</i> , 2017, 135, 1509-1517.	1.6	117
101	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization. <i>JACC: Heart Failure</i> , 2017, 5, 169-178.	1.9	34
102	Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations. <i>International Journal of Cardiology</i> , 2017, 240, 279-284.	0.8	87
103	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	13.9	257
104	The Role of Implantable Hemodynamic Monitors to Manage Heart Failure. <i>Cardiology Clinics</i> , 2017, 35, 273-279.	0.9	5
105	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2428-2445.	1.2	88
106	Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	15
107	Predictors of short-term clinical response to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 1056-1063.	2.9	27
108	Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1875-1886.	1.2	198

#	ARTICLE	IF	CITATIONS
109	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53
110	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2490-2500.	1.2	114
111	Implantable Hemodynamic Monitoring for Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2017, 70, 389-398.	1.2	96
112	Evaluating the quality of implantation of percutaneous ventricular restoration device (Parachute®) by cardiac computed tomography. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E104-E111.	0.7	1
113	Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials. <i>European Journal of Heart Failure</i> , 2017, 19, 426-433.	2.9	46
114	Effect of cardiac resynchronization therapy in patients with diabetes randomized in <sc>EchoCRT</sc>. <i>European Journal of Heart Failure</i> , 2017, 19, 80-87.	2.9	5
115	The Davis Heart and Lung Research Institute. <i>Circulation Research</i> , 2017, 120, 1068-1071.	2.0	1
116	Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 204-212.	1.9	30
117	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1521-1532.	13.9	204
118	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 320-328.	0.4	26
119	Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remedâ[®] System. <i>European Journal of Heart Failure</i> , 2016, 18, 1386-1393.	2.9	43
120	Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. <i>Lancet</i> , The, 2016, 388, 974-982.	6.3	142
121	Cardiac computed tomography assessment of the near term impact of percutaneous ventricular restoration therapy (parachute[®]) on mitral valve geometry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E45-51.	0.7	2
122	Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	76
123	Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 971-980.	1.5	39
124	Current and future developments in the field of central sleep apnoea. <i>Europace</i> , 2016, 18, 1123-1134.	0.7	21
125	Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. <i>JACC: Heart Failure</i> , 2016, 4, 333-344.	1.9	112
126	Current treatment approaches and trials in central sleep apnea. <i>International Journal of Cardiology</i> , 2016, 206, S22-S27.	0.8	10

#	ARTICLE	IF	CITATIONS
127	Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. <i>Lancet, The</i> , 2016, 387, 453-461.	6.3	478
128	Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2016, 37, 49-59.	1.0	43
129	The Aliskiren Trial to Minimize <scp>OutcomeS</scp> in Patients with <scp>HEart</scp> failure trial (<scp>ATMOSPHERE</scp>): revised statistical analysis plan and baseline characteristics. <i>European Journal of Heart Failure</i> , 2015, 17, 1075-1083.	2.9	18
130	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). <i>Journal of Cardiac Failure</i> , 2015, 21, 479-488.	0.7	69
131	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2015, 17, 1066-1074.	2.9	85
132	Mechanisms and Clinical Consequences of Untreated Central Sleep Apnea in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 65, 72-84.	1.2	120
133	Sleep disordered breathing and post-discharge mortality in patients with acute heart failure. <i>European Heart Journal</i> , 2015, 36, 1463-1469.	1.0	215
134	The Role of Implantable Hemodynamic Monitors to Manage Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, 183-189.	1.0	6
135	The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2015, 36, 1983-1989.	1.0	65
136	Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: Insights from a wireless pulmonary artery pressure monitoring system. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 438-447.	0.3	24
137	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 487-496.	1.9	204
138	MG53-mediated cell membrane repair protects against acute kidney injury. <i>Science Translational Medicine</i> , 2015, 7, 279ra36.	5.8	103
139	<scp>d</scp>-Ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2015, 9, 56-65.	1.0	25
140	Center of excellence for mobile sensor data-to-knowledge (MD2K). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 1137-1142.	2.2	48
141	Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2015, 3, 691-700.	1.9	10
142	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea. <i>JACC: Heart Failure</i> , 2015, 3, 360-369.	1.9	114
143	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation in Patients With Moderately Reduced Left Ventricular Ejection Fraction and a Narrow QRS Duration: Study Rationale and Design. <i>Journal of Cardiac Failure</i> , 2015, 21, 16-23.	0.7	38
144	Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 329-337.	0.3	56

#	ARTICLE	IF	CITATIONS
145	Population Study of Urban, Rural, and Semiurban Regions for the Detection of Endovascular Disease and Prevalence of Risk Factors and Holistic Intervention Study: Rationale, Study Design, and Baseline Characteristics of PURSE-HIS. <i>Global Heart</i> , 2015, 10, 281.	0.9	8
146	Abstract 15860: Arterial and Cardiac Hemodynamics in Advanced HF Patients Implanted With the C-Pulse Counterpulsation Device: Implications for Myocardial Recovery. <i>Circulation</i> , 2015, 132, .	1.6	0
147	Abstract 19802: Implantable Hemodynamic Monitoring Reduces Heart Failure Hospitalizations Due to Congestion Regardless of Perfusion Status. <i>Circulation</i> , 2015, 132, .	1.6	0
148	Trials of implantable monitoring devices in heart failure: which design is optimal?. <i>Nature Reviews Cardiology</i> , 2014, 11, 576-585.	6.1	31
149	Percutaneous Ventricular Restoration Using the Parachute Device in Patients With Ischemic Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 752-758.	1.6	54
150	Ambulatory Extra-Aortic Counterpulsation in Patients With Moderate to Severe Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 526-533.	1.9	21
151	Novel Non-pharmacological Approaches to Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 263-265.	1.1	8
152	Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 935-944.	1.6	360
153	Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , 2014, 175, 30-37.	0.8	37
154	Abstract 215: Principal Components Analysis in a South Asian Population: Cardiovascular Risk Variable Clustering and Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, .	1.1	0
155	Abstract 16318: Clinical and Economic Value of Maximizing Response to Cardiac Resynchronization Therapy (CRT): Evidence From 5 Randomized Controlled Trials. <i>Circulation</i> , 2014, 130, .	1.6	0
156	Abstract 16744: Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalizations and All-Cause 30-Day Readmissions in Medicare-Eligible Patients With NYHA Class III Heart Failure: Results From the CHAMPION Trial. <i>Circulation</i> , 2014, 130, .	1.6	4
157	Wearable Cardioverter-Defibrillator Use in Patients Perceived to Be at High Risk Early Post-Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2000-2007.	1.2	170
158	Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta 1 389 Arg/Gly Adrenergic Receptor Polymorphism. <i>JACC: Heart Failure</i> , 2013, 1, 338-344.	1.9	43
159	Devices in the management of advanced, chronic heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 98-110.	6.1	56
160	Remote Heart Failure Monitoring. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 556-564.	0.4	3
161	Disease management: remote monitoring in heart failure patients with implantable defibrillators, resynchronization devices, and haemodynamic monitors. <i>Europace</i> , 2013, 15, i40-i46.	0.7	36
162	Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. <i>Kidney International</i> , 2012, 82, 1215-1222.	2.6	35

#	ARTICLE	IF	CITATIONS
163	Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. <i>Kidney International</i> , 2012, 82, 1223-1230.	2.6	30
164	Burden of atrial fibrillation and poor rate control detected by continuous monitoring and the risk for heart failure hospitalization. <i>American Heart Journal</i> , 2012, 164, 616-624.	1.2	45
165	Combinatorial Pharmacogenetic Interactions of Bucindolol and β_1 , β_2 Adrenergic Receptor Polymorphisms. <i>PLoS ONE</i> , 2012, 7, e44324.	1.1	55
166	CHAMPION— Trial Rationale and Design: The Long-Term Safety and Clinical Efficacy of a Wireless Pulmonary Artery Pressure Monitoring System. <i>Journal of Cardiac Failure</i> , 2011, 17, 3-10.	0.7	143
167	Hemodynamic Factors Associated With Acute Decompensated Heart Failure: Part 2—Use in Automated Detection. <i>Journal of Cardiac Failure</i> , 2011, 17, 366-373.	0.7	25
168	Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. <i>Lancet</i> , 2011, 377, 658-666.	6.3	1,345
169	Intrathoracic Impedance vs Daily Weight Monitoring for Predicting Worsening Heart Failure Events: Results of the Fluid Accumulation Status Trial (FAST). <i>Congestive Heart Failure</i> , 2011, 17, 51-55.	2.0	185
170	Nesiritide in Acute Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials. <i>Clinical Cardiology</i> , 2010, 33, 484-489.	0.7	14
171	Treatment of Anemia With Darbepoetin Alfa in Heart Failure. <i>Congestive Heart Failure</i> , 2010, 16, 87-95.	2.0	6
172	Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study. <i>Clinical and Translational Science</i> , 2010, 3, 249-253.	1.5	33
173	Pharmacologic Therapies Across the Continuum of Left Ventricular Dysfunction. <i>American Journal of Cardiology</i> , 2008, 102, 21C-28C.	0.7	19
174	Switching to Evidence-Based Once-Daily β -Blockers for Improved Adherence to Medication Across the Continuum of Post-Myocardial Infarction Left Ventricular Dysfunction and Heart Failure. <i>Congestive Heart Failure</i> , 2008, 14, 272-280.	2.0	4
175	Predictors of In-Hospital Mortality in Patients Hospitalized for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 347-356.	1.2	506
176	Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1834-1843.	1.2	1,060
177	A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: Rationale, design, and baseline patient characteristics. <i>American Heart Journal</i> , 2008, 156, 641-648.e1.	1.2	36
178	Optimization of Cardiac Resynchronization Devices Using Acoustic Cardiography: A Comparison to Echocardiography. <i>Congestive Heart Failure</i> , 2006, 12, 25-31.	2.0	5
179	Response to Abraham. <i>Circulation</i> , 2006, 114, 2692-2698.	1.6	10
180	Clinical and Hemodynamic Effects of Nesiritide (B-Type Natriuretic Peptide) in Patients With Decompensated Heart Failure Receiving β Blockers. <i>Congestive Heart Failure</i> , 2005, 11, 59-64.	2.0	15

#	ARTICLE	IF	CITATIONS
181	Cardiac Resynchronization Therapy in Heart Failure. <i>Annals of Internal Medicine</i> , 2005, 142, 307.	2.0	1
182	In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications. <i>Journal of the American College of Cardiology</i> , 2005, 46, 57-64.	1.2	712
183	Effects of Cardiac Resynchronization on Disease Progression in Patients With Left Ventricular Systolic Dysfunction, an Indication for an Implantable Cardioverter-Defibrillator, and Mildly Symptomatic Chronic Heart Failure. <i>Circulation</i> , 2004, 110, 2864-2868.	1.6	477
184	Preventing cardiovascular events in patients with diabetes mellitus. <i>American Journal of Medicine</i> , 2004, 116, 39-46.	0.6	18
185	Practical considerations for switching beta-blockers in heart failure patients. <i>Reviews in Cardiovascular Medicine</i> , 2004, 5 Suppl 1, S36-44.	0.5	0
186	Cardiac Resynchronization Therapy for Heart Failure. <i>Circulation</i> , 2003, 108, 2596-2603.	1.6	293
187	Cardiac Resynchronization Therapy for the Management of Chronic Heart Failure. <i>The American Heart Hospital Journal</i> , 2003, 1, 55-61.	0.2	12
188	Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. <i>Reviews in Cardiovascular Medicine</i> , 2003, 4 Suppl 2, S30-7.	0.5	8
189	Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk. <i>Reviews in Cardiovascular Medicine</i> , 2003, 4 Suppl 3, S30-6.	0.5	1
190	Comprehensive Pharmacologic Management Strategies for Heart Failure. , 0, , 15-34.		1
191	Clinical Trials Supporting Current Indications for CRT. , 0, , 261-276.		0